Vertex Pharmaceuticals Stock Dips Despite Broader Market Gains; Analysts Bullish on Earnings Growth Potential Despite Valuation Premium
-
Vertex Pharmaceuticals (VRTX) stock dipped 0.09% while the broader market gained. The stock has seen an 8.6% increase over the past month.
-
Analysts expect Vertex to post Q4 EPS of $4.08, up 8.51% year-over-year, on revenue of $2.5B, up 8.52%.
-
Positive estimate revisions are a sign of optimism about the company's outlook and correlated with share price momentum. VRTX recently saw a 0.15% upward estimate revision.
-
VRTX has a Forward P/E ratio of 26.57 vs the industry average of 23.69, suggesting it trades at a premium comparatively.
-
The Medical - Biomedical and Genetics industry ranks in the top 39% of Zacks-covered industries, suggesting strong performance potential.